Prevalence and Clinical Correlates of Metabolic Syndrome in Nigerians Living with Human Immunodeficiency Virus/Acquired Immunodeficiency Syndrome

Ayodele, Olugbenga Edward; Akinboro, A.O.; Akinyemi, Suliat Omolola; Adepeju, A A; Akinremi, Oluwaseun Akinsanmi; Alao, Christiana Adeola; Popoola, Adetoun Adedayo

doi:10.1089/met.2012.0050

Cited by 39 publications

(43 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…1-3,7,9,11,13 It is also reported an association with a long exposure to ARV drugs. 1,5,10,13 But, beyond 54 months of treatment, our findings did not confirm this, strengthening observations on the early onset of metabolic disorders in African HIV-infected cohorts. 11,20 Conclusions sometimes differ on the role of initial immune deficiency.…”

Section: Discussioncontrasting

confidence: 89%

“…Its determining factors differed sometimes from those reported in the literature. The frequency of metabolic syndrome varies from 10% to 21% in patients receiving HAART in Africa, 5,10,11 and estimations are from 11.4% to 52.2% in Europe, 3 10,17 Similarly, the role of the virus is discussed, and the incidence of metabolic syndrome doesn't differ in HIV-infected patients compared to noninfected patients or the general population. 1,2,13,15,16,18 Despite these controversies, and because of HIV infection is a cardiovascular risk factor, metabolic syndrome should more preoccupy in HIV-infected patients.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Features of Metabolic Syndrome and Its Associated Factors during Highly Active Antiretroviral Therapy in Ouagadougou (Burkina Faso)

Guira

Tiéno

Diendéré

et al. 2015

J Int Assoc Provid AIDS Care

View full text Add to dashboard Cite

show abstract

Section: Discussioncontrasting

confidence: 89%

Section: Discussionmentioning

confidence: 99%

Features of Metabolic Syndrome and Its Associated Factors during Highly Active Antiretroviral Therapy in Ouagadougou (Burkina Faso)

Guira

Tiéno

Diendéré

et al. 2015

J Int Assoc Provid AIDS Care

View full text Add to dashboard Cite

show abstract

“…Indeed, PLWHA, aged over 50, have a history of the disease and treatment history longer than the younger subjects and thus would develop more of metabolic abnormalities. Various studies confirm these facts [5]- [8] [20]. In our study, a difference of one year of age significantly increased by 0.3% the risk to develop metabolic syndrome.…”

Section: Discussionsupporting

confidence: 89%

“…In Africa, the frequency of metabolic syndrome varies from 10% to 21% in patients receiving ART [5] [7] [8]. This frequency is strongly related to the diagnosis criteria which are those of IDF (International Diabetes Federation) or those of NCEP-ATP III.…”

Section: Discussionmentioning

confidence: 99%

Influence of Antiretroviral Therapy on the Metabolic Profile of People Living with HIV Followed at University Hospital, Cotonou, Benin

Zannou¹,

Azon-Kouanou²,

Ahomadegbe³

et al. 2015

OJIM

View full text Add to dashboard Cite

Introduction: Since the advent of antiretroviral therapy, the vital prognosis of people living with HIV (PLWHA) has improved significantly. However, the risk of metabolic complications is high, thus making the bed of cardiovascular disease. Our objective was to compare the prevalence of metabolic abnormalities among PLWHA receiving ARVs to that observed in those who are not treated. Methods: We conducted a cross-sectional study (January to April 2010) at the PLWHA ambulatory care center of national university hospital (CNHU-Hubert K. Maga) in Cotonou, Bénin. We recruited 420 PLWHA (210 treated for at least 6 months and 210 untreated). We determined the prevalence of metabolic syndrome (MS) defined by the criteria of NCEP-ATP III, and the prevalence of abnormal glucose and lipid, and lipodystrophy. Association between metabolic syndrome and ARVs used was analyzed by binomial regression. Confidence intervals were calculated at 95% and 5% alpha level. Results: The prevalence of MS was 16% (18% of patients treated vs. 13% of non-treated, p = 0.18). That of hyperglycemia was 18% (30% of patients treated vs. 6% of untreated; p < 0.001) and of diabetes 7% (12% of patients treated vs 2% of untreated; p < 0.0001). *Corresponding author. D. M. Zannou et al. 107The total cholesterol prevalence was 29% (44% of treated vs 13% of untreated; p <0.02). That of lipodystrophy in 210 patients was 29% (lipoatrophy16%, lipohypertrophy 8%, mixed form 6%).

show abstract

“…One report among people with Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS) on HAART, using the three criteria we studied revealed a moderate to substantial agreement among the criteria (k= 0.583-0.878). 46 Various studies 47,48,49 found substantial agreement between the IDF and ATP criteria while some found moderate agreement between the two criteria. These suggest that the two criteria identify essentially the people with MS equally.…”

Section: Concordance Among Definitions Of Metabolic Syndromementioning

confidence: 99%

Metabolic Syndrome among Apparently Healthy Nigerians with the Harmonized Criteria: Prevalence and Concordance with the International Diabetes Federation (IDF) and Third Report of the National Cholesterol Education Programme - Adult Treatment Panel III (NCEP-ATP III) Criteria

Raimi¹,

Odusan²,

Fasanmade³

et al. 2017

JCDR

View full text Add to dashboard Cite

Background:The prevalence of metabolic syndrome varies by the definition used and the population studied. In order to make comparison among various studies possible, a new criterion which harmonizes the previous definitions was proposed. This study aims to determine the prevalence of metabolic syndrome with the harmonized criteria, and its concordance with the International Diabetes Federation (IDF), and National Cholesterol Education Programme-Adult Treatment Panel (NCEP-ATP III) criteria. Methods: One hundred and two apparently healthy individuals who participated in health screening were evaluated for metabolic syndrome. The blood pressure and anthropometric parameters were measured according to standard protocol, and fasting plasma glucose and lipid profile were determined. Metabolic syndrome was defined using the Harmonized, IDF and ATP III criteria. The agreement among the three diagnostic criteria was determined with kappa statistics. Results: The prevalence of metabolic syndrome was 4.9%, 3.9% and 4.9% with harmonized, IDF, and NCEP-ATP criteria respectively. Compared to the males, the prevalence was greater in females: Males vs Females (harmonized, 2.2% vs 7.0%; IDF, 2.2% vs 5.3%; NCEP-ATP III, 2.2% vs 7.0%). The commonest risk factor in this population was low HDL occurring in 93.0% and 37.8% of females and males respectively, followed by central obesity (50.9% in females, 13.3% in males with harmonized and IDF criteria; 33.3% in females, 4.4% in males with NCEP-ATP criteria), hypertension (12.5% in females, 18.6% in males) and hyperglycaemia (4.2% in females, 0.0% in males) in that order. None of the participants had elevated Triglyceride. There was a substantial concordance between the harmonized and the IDF (k=0.884) as well as the harmonized and NCEP-ATP III (k=1.000) definitions. Conclusion: The prevalence of metabolic syndrome was low in this population. There was a substantial agreement among the three diagnostic criteria.

show abstract

Prevalence and Clinical Correlates of Metabolic Syndrome in Nigerians Living with Human Immunodeficiency Virus/Acquired Immunodeficiency Syndrome

Cited by 39 publications

References 32 publications

Features of Metabolic Syndrome and Its Associated Factors during Highly Active Antiretroviral Therapy in Ouagadougou (Burkina Faso)

Features of Metabolic Syndrome and Its Associated Factors during Highly Active Antiretroviral Therapy in Ouagadougou (Burkina Faso)

Influence of Antiretroviral Therapy on the Metabolic Profile of People Living with HIV Followed at University Hospital, Cotonou, Benin

Metabolic Syndrome among Apparently Healthy Nigerians with the Harmonized Criteria: Prevalence and Concordance with the International Diabetes Federation (IDF) and Third Report of the National Cholesterol Education Programme - Adult Treatment Panel III (NCEP-ATP III) Criteria

Contact Info

Product

Resources

About